Aldeyra Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 10
- Market Cap
- $319M
- Website
- http://www.aldeyra.com
- Introduction
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
- Conditions
- Conjunctivitis, Allergic
- Interventions
- Drug: ADX-102 Ophthalmic Drops (0.5%)Drug: Vehicle of ADX-102 Ophthalmic DropsDrug: ADX-102 Ophthalmic Drops (0.1%)
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT03012165
- Locations
- 🇺🇸
Eye Care Centers Management, Morrow, Georgia, United States
🇺🇸Silverstein Eye Centers, Kansas City, Missouri, United States
🇺🇸Apex Eye Clinical Research, Mason, Ohio, United States
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
- Conditions
- Seasonal AllergiesAllergic Conjunctivitis
- Interventions
- Drug: NS2 Ophthalmic Drops (0.5%)Drug: NS2 Ophthalmic Drops Vehicle (0.0%)
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02578914
- Locations
- 🇨🇦
Inflamax Research Inc., Mississauga, Ontario, Canada
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02406209
- Locations
- 🇺🇸
Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States
🇺🇸Lifelong Vision Foundation, Chesterfield, Missouri, United States
🇺🇸Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
- Conditions
- Sjögren-Larsson Syndrome
- Interventions
- Drug: Active topical NS2 1% dermatologic creamDrug: Vehicle placebo 0.0% NS2 dermatologic cream
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02402309
- Locations
- 🇺🇸
Penn State Hershey Medical Center - Department of Dermatology, Hershey, Pennsylvania, United States
🇺🇸Pediatric and General Dermatology, Fairfax, Virginia, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States